Stay updated on Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check13 days agoChange DetectedThe latest version adds a Contacts/Locations section and a Study Status update to the record. These additions improve access to study contact information and the current recruitment status.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a site-wide funding/operating status notice and Revision: v3.4.1; removed Revision: v3.4.0.SummaryDifference0.3%

- Check28 days agoChange DetectedUI improvements include a glossary toggle and color-coded highlights (green for additions, red for deletions, and highlighting of changes) in the study record history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedA new site revision label, v3.3.4, was added and the previous revision, v3.3.3, was removed. This represents a routine background update with no changes to trial data or user-facing functionality.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page now includes a new entry: Revision: v3.3.3. The footer link 'HHS Vulnerability Disclosure' and the older 'Revision: v3.3.2' have been removed.SummaryDifference0.1%

- Check92 days agoChange DetectedRecord History shows a new metadata revision (Revision: v3.3.2) added and an older revision (Revision: v3.2.0) removed; this reflects version metadata rather than content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.